BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival

Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.

BridgeBio’s transthyretin amyloidosis drug Attruby elicited notable improvements in survival and hospitalization rates, pointing to its potential “superiority” over competing products from Pfizer, analysts say.

In the Phase 3 ATTRibute-CM study, BridgeBio enrolled more than 630 patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), who were randomly assigned to receive either Attruby or placebo. An additional analysis of the trial, conducted by the Mater Misericordiae University Hospital in Ireland, employed anchored matching to indirectly compare Attruby to Pfizer’s tafamidis, marketed as Vyndaqel or Vyndamax.